Illumina (NASDAQ:ILMN) Posts Earnings Results, Misses Expectations By $0.06 EPS

Illumina (NASDAQ:ILMN) released its earnings results on Thursday. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06), Zacks reports. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%.

Illumina Stock Down 1.5 %

ILMN traded down $1.88 on Thursday, reaching $122.80. 2,145,761 shares of the company traded hands, compared to its average volume of 1,834,142. The stock’s 50 day moving average price is $137.80 and its 200-day moving average price is $135.42. Illumina has a 52-week low of $100.08 and a 52-week high of $156.66. The company has a market cap of $19.48 billion, a price-to-earnings ratio of -12.33 and a beta of 1.10. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of research reports. Morgan Stanley dropped their target price on shares of Illumina from $156.00 to $150.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Royal Bank of Canada boosted their target price on shares of Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Leerink Partners boosted their target price on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a report on Thursday, October 17th. Finally, Robert W. Baird lifted their target price on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Eight research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $164.84.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.